文献速递认知障碍与痴呆

阿尔茨海默病抵抗与韧性:澄清临床前研究的术语

Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies.
PubMed 文献 · Neurology · 2018-03-28

本文提出一个概念框架,将临床前阿尔茨海默病中避免病理(无显著淀粉样蛋白或tau病理且认知正常)定义为抵抗,将应对病理(有显著病理但认知正常)定义为韧性,并给出术语使用建议、研究设计讨论及在假设构建和结果解释中的应用。

要点

  • 抵抗指无显著淀粉样蛋白或tau病理且认知正常。
  • 韧性指有显著淀粉样蛋白或tau病理但认知正常。
  • 该框架可用于统一临床前研究中的假设、设计和解释。

核心结论

  • 应用该框架可为研究者提供一致的术语和框架,以就识别可能预防淀粉样蛋白或tau病理或延缓认知障碍的因素达成共识。

研究设计与样本

  • 本文为概念性框架文章,基于现有脑储备、认知储备、脑维持、神经保护与补偿等概念提出新术语。

主要发现

  • 文章将抵抗定义为避免病理,即无显著淀粉样蛋白或tau病理且认知正常。
  • 文章将韧性定义为应对病理,即有显著淀粉样蛋白或tau病理但认知正常。
  • 文章讨论了该术语在研究机制和因素、与现有概念的互补性以及不同研究设计和方法学中的应用。

关键数值与推荐

  • 抵抗的操作性定义为无显著淀粉样蛋白或tau病理且认知正常。
  • 韧性的操作性定义为有显著淀粉样蛋白或tau病理但认知正常。

临床怎么用

  • 作者建议在临床前阿尔茨海默病研究中采用抵抗与韧性的术语来构建假设、设计研究和解释结果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preventing or delaying Alzheimer disease (AD) through lifestyle interventions will come from a better understanding of the mechanistic underpinnings of (1) why a significant proportion of elderly remain cognitively normal with AD pathologies (ADP), i.e., amyloid or tau; and (2) why some elderly individuals do not have significant ADP. In the last decades, concepts such as brain reserve, cognitive reserve, and more recently brain maintenance have been proposed along with more general notions such as (neuro)protection and compensation. It is currently unclear how to effectively apply these concepts in the new field of preclinical AD specifically separating the 2 distinct mechanisms of coping with pathology vs avoiding pathology. We propose a simplistic conceptual framework that builds on existing concepts using the nomenclature of resistance in the context of avoiding pathology, i.e., remaining cognitively normal without significant ADP, and resilience in the context of coping with pathology, i.e., remaining cognitively normal despite significant ADP. In the context of preclinical AD studies, we (1) define these concepts and provide recommendations (and common scenarios) for their use; (2) discuss how to employ this terminology in the context of investigating mechanisms and factors; (3) highlight the complementarity and clarity they provide to existing concepts; and (4) discuss different study designs and methodologies. The application of the proposed framework for framing hypotheses, study design, and interpretation of results and mechanisms can provide a consistent framework and nomenclature for researchers to reach consensus on identifying factors that may prevent ADP or delay the onset of cognitive impairment.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies. Neurology. 2018. PMID: 29592885. doi:10.1212/WNL.0000000000005303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。